CTOs on the Move

The Bailey Health Group

www.mbaileygroup.com

 
The Bailey Group is the largest pure employee benefits firm in Northeast Florida with over 70 full-time representatives, each dedicated to being an extension of their clients` HR departments.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.mbaileygroup.com
  • 1200 Plantation Island Drive Suite 210
    Saint Augustine, FL USA 32080
  • Phone: 904.461.1800

Executives

Name Title Contact Details

Similar Companies

Marlow Manor Assisted Living

Marlow Manor Assisted Living is a Anchorage, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Interactions Inc

Community Interactions Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Swarthmore, PA. To find more information about Community Interactions Inc, please visit www.communityinteractions.org

Invent Bio-Med

Invent Bio-Med is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boehringer Ingelheim

For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. We are proud of addressing some of the most challenging healthcare issues. Our vision – value through innovation – has always characterized our collaborative work, and is for us simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.